QURE vs RARE · rev $16.1M vs rev $350.0M
Uniqure NV (QURE) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Uniqure NV (QURE) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported QURE revenue for 2025-12-31 was $16.1M. Net income was -$199.0M. Revenue was down 40.6% from 2024-12-31 to 2025-12-31. QURE currently screens at market cap $3.04B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
QURE currently screens at market cap $3.04B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the QURE and RARE stock pages for the full models.
Not investment advice.